Evidence map›Paper›PMID 24699908›Full record

ArticlePloS one2014

Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine.

Emily Eva Holmes, Maria Jung, Sebastian Meller, Annette Leisse, Verena Sailer, Julie Zech, Martina Mengdehl, Leif-Alexander Garbe, Barbara Uhl, Glen Kristiansen and 1 more

Registry-linked trialOpen access · goldAbstract readEvaluation Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06662591 (A Multi-Center Multi-Omics Approach for Investigating Genetic and Epigenetic Mechanisms in Autism Spectrum Disorder), which is not on this map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06662591 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Multi-Center Multi-Omics Approach for Investigating Genetic and Epigenetic Mechanisms in Autism Spectrum Disorder

Typeobservational_patient_registrySponsorResearch and Treatment Society of Genetic DisordersRan2025 to 2028Enrolled3,000ConditionsAutism Spectrum Disorder (ASD)
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Single-cell bisulfite-free 5mC and 5hmC sequencing with high sensitivity and scalability.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Emily Eva HolmesUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Maria JungUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Sebastian MellerUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Annette LeisseUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Verena SailerUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Julie ZechBerlin Institute of Technology (TU Berlin), Biotechnology, Berlin, Germany.
Martina MengdehlBerlin Institute of Technology (TU Berlin), Biotechnology, Berlin, Germany.
Leif-Alexander GarbeBerlin Institute of Technology (TU Berlin), Biotechnology, Berlin, Germany.
Barbara UhlUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Glen KristiansenUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
Dimo DietrichUniversity Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany.
University Hospital Bonn · DETechnische Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methylation analyses usually require a preceding bisulfite conversion of the DNA. The choice of an appropriate kit for a specific application should be based on the specific performance requirements with regard to the respective sample material. In this study, the performance of nine kits was evaluated: EpiTect Fast FFPE Bisulfite Kit, EpiTect Bisulfite Kit, EpiTect Fast DNA Bisulfite Kit (Qiagen), EZ DNA Methylation-Gold Kit, EZ DNA Methylation-Direct Kit, EZ DNA Methylation-Lightning Kit (Zymo Research), innuCONVERT Bisulfite All-In-One Kit, innuCONVERT Bisulfite Basic Kit, innuCONVERT Bisulfite Body Fluids Kit (Analytik Jena). The kit performance was compared with regard to DNA yield, DNA degradation, DNA purity, conversion efficiency, stability and handling using qPCR, UV, clone sequencing, HPLC, and agarose gel electrophoresis. All kits yielded highly pure DNA suitable for PCR analyses without PCR inhibition. Significantly higher yields were obtained when using the EZ DNA Methylation-Gold Kit and the innuCONVERT Bisulfite kits. Conversion efficiency ranged from 98.7% (EpiTect Bisulfite Kit) to 99.9% (EZ DNA Methylation-Direct Kit). The inappropriate conversion of methylated cytosines to thymines varied between 0.9% (innuCONVERT Bisulfite kits) and 2.7% (EZ DNA Methylation-Direct Kit). Time-to-result ranged from 131 min (innuCONVERT kits) to 402 min (EpiTect Bisulfite Kit). Hands-on-time was between 66 min (EZ DNA Methylation-Lightning Kit) and 104 min (EpiTect Fast FFPE and Fast DNA Bisulfite kits). Highest yields from formalin-fixed and paraffin-embedded (FFPE) tissue sections without prior extraction were obtained using the innuCONVERT Bisulfite All-In-One Kit while the EZ DNA Methylation-Direct Kit yielded DNA with only low PCR-amplifiability. The innuCONVERT Bisulfite All-In-One Kit exhibited the highest versatility regarding different input sample materials (extracted DNA, tissue, FFPE tissue, cell lines, urine sediment, and cellular fractions of bronchial aspirates, pleural effusions, ascites). The innuCONVERT Bisulfite Body Fluids Kit allowed for the analysis of 3 ml plasma, serum, ascites, pleural effusions and urine.

Indexed as

DNA MethylationBody FluidsCell LineDNAHumansReagent Kits, DiagnosticSulfitesDNAhydrogen sulfiteReagent Kits, DiagnosticSulfites

Identifiers

PMID24699908
PMCPMC3974851
OpenAlexW2064302386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.